Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On-site exposure to clinical epilepsy practice for experimental scientists engaged in epilepsy research: A pilot study by the ILAE commission on neurobiology.

Epilepsia open·2026
Same author

Association of ictal aphasia with hypoperfusion in language areas in temporal lobe epilepsy patients.

Epileptic disorders : international epilepsy journal with videotape·2023
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

32.3K

Prognostic factors in ALS: different approaches to the same problem.

Maria Cristina Vázquez1, Abayubá Perna1, Mariana Legnani1

  • 1Universidad de la República, Hospital de Clínicas, Departamento de Neurología, Montevideo, Uruguay.

Arquivos De Neuro-Psiquiatria
|June 20, 2025
PubMed
Summary

This study analyzed amyotrophic lateral sclerosis (ALS) survival in Uruguay, finding median survival varied by patient group. Key factors influencing survival included age at onset and disease progression.

More Related Videos

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.3K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K

Related Experiment Videos

Last Updated: Jun 27, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

32.3K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.3K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K

Area of Science:

  • Neurology
  • Epidemiology
  • Clinical Research

Background:

  • Amyotrophic lateral sclerosis (ALS) natural history and survival data are limited in South America.
  • Understanding prognostic factors is crucial for patient care and research.

Purpose of the Study:

  • To describe the survival of Uruguayan ALS patients.
  • To identify clinical and demographic factors predicting survival in this population.

Main Methods:

  • Kaplan-Meier method for survival analysis.
  • Cox proportional hazards models (classic, stratified, truncated) to identify prognostic predictors.
  • Analysis of 166 definite and probable ALS patients with a median follow-up of 13.6 years.

Main Results:

  • Median survival from diagnosis was 33 months for prevalent cases, 22 months for exhaustive incident cases, and 14 months for non-exhaustive incident cases.
  • Overall median survival from onset was 37 months, and from diagnosis was 23 months.
  • Significant prognostic factors included age at onset, bulbar onset, clinical form, and progression rate.

Conclusions:

  • This study provides essential data on ALS survival in Uruguay.
  • Identified prognostic factors can inform clinical management and future research.
  • Highlights the impact of recruitment bias and onset determination on survival analysis in ALS studies.